CureDuchenne is pleased to see our biotech partner Capricor Therapeutics progress with their HOPE-Duchenne clinical trial.
Capricor announced today the treatment of the first patient with Duchenne muscular dystrophy-related cardiomyopathy with CAP-1002 in the HOPE-Duchenne Phase I/II clinical trial. The patient was treated at the Cincinnati Children’s Hospital Medical Center under the direction of Dr. John Jefferies, the national principal investigator for the HOPE-Duchenne trial. Capricor is continuing to enroll patients at Cincinnati Children’s and at Cedars-Sinai Heart Institute in Los Angeles.
CureDuchenne helped fund this important human trial that addresses cardiac function. Cardiomyopathy is currently the leading cause of death in patients with Duchenne. CAP-1002 is Capricor’s allogeneic cardiosphere-derived stem cell therapy.
CureDuchenne continues to fund Duchenne research to accelerate drugs into human clinical trials. Duchenne impacts the whole body and that is why it is critical to find treatments that address all aspects of the disease. CureDuchenne has funded exon skipping, gene therapy, anti-inflammatory, anti-fibrotic as well cardiac treatments.
Duchenne patients will most likely need a cocktail of drugs that work together to get closer to a cure. We will continue to accelerate drug development and fund promising treatments until there is a cure for all those with Duchenne.
For more information, please visit: https://capricor.com/hope/ or ClinicalTrials.gov (NCT02485938).